Observations placeholder
Tambocor
Identifier
005075
Type of Spiritual Experience
Background
A description of the experience
Flecainide acetate
Flecainide was originally sold under the trade name Tambocor and is available under the trade names Almarytm, Apocard, Ecrinal, and Flécaine.
It is an antiarrhythmic agent used to prevent and treat tachyarrhythmias (abnormal fast rhythms of the heart), including paroxysmal atrial fibrillation (episodic irregular heartbeat originating in the upper chamber of the heart), paroxysmal supraventricular tachycardia (episodic rapid but regular heartbeat originating in the atrium), and ventricular tachycardia (rapid rhythms of the lower chambers of the heart). Flecainide works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential. This thereby slows conduction of the electrical impulse within the heart.
The dosing of flecainide is rather critical and should take into account the individual's other medications and comorbid conditions and how they may affect the metabolism of flecainide. Flecainide interacts with numerous pharmaceuticals and can potentiate the effects of other myocardial depressants and AV node blocking agents. In addition, flecainide can decrease the metabolism or elimination of many (but not all) agents that use the cytochrome P450 enzyme system.
At the wrong dosage the drug is a toxin. It can kill you. “Studies have shown an increased mortality when flecainide is used to suppress ventricular extrasystoles in the setting of acute myocardial infarction” and “Due to the narrow therapeutic index of flecainide, physicians should be alert for signs of toxicity before life-threatening arrhythmias occur”
Furthermore, the results of a medical study known as the Cardiac Arrhythmia Suppression Trial (CAST) demonstrated that patients with structural heart disease and ventricular arrhythmias, could suffer a fatal arrhythmia.
On Jan, 08, 2017 1,718 people reported to have side effects when taking Tambocor. Among them, 7 people (0.41%) have Hallucination.
On Jan, 29, 2017 1,718 people reported to have side effects when taking Tambocor.
Among them, 3 people (0.17%) have Hallucination, Auditory
On Jan, 04, 2017 3,629 people reported to have side effects when taking Flecainide Acetate. Among them, 14 people (0.39%) have Hallucination
On Mar, 27, 2015: 1,374 people reported to have side effects when taking Tambocor. Among them, 20 people (1.46%) have Death.
Time on Tambocor when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 71.43% | 14.29% | 0.00% | 0.00% | 14.29% | 0.00% | 0.00% |